A trimeric recombinant form of soluble CD40L, recently tested in Phase I studies with lymphoma or solid tumour bearing patients, showed limited toxicity, indicating the potential feasibility of this therapeutic approach in NB patients (Vonderheide et al, 2001a, 2001b). This evidence concerns the gene CD40LG and lymphoma.